Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
95% of the 558 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. PETS: No Debt )
PETS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.91
PETS's Equity to Asset is ranked higher than
99% of the 558 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. PETS: 0.91 )
PETS' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.95
Current: 0.91

-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
98% of the 427 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.31 vs. PETS: No Debt )
PETS' s 10-Year Interest Coverage Range
Min: 15.27   Max: 9999.99
Current: No Debt

15.27
9999.99
F-Score: 7
Z-Score: 28.57
M-Score: -1.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.50
PETS's Operating margin (%) is ranked higher than
97% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.50 vs. PETS: 11.50 )
PETS' s 10-Year Operating margin (%) Range
Min: -26.37   Max: 17.02
Current: 11.5

-26.37
17.02
Net-margin (%) 7.33
PETS's Net-margin (%) is ranked higher than
96% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.26 vs. PETS: 7.33 )
PETS' s 10-Year Net-margin (%) Range
Min: -28.25   Max: 10.91
Current: 7.33

-28.25
10.91
ROE (%) 23.95
PETS's ROE (%) is ranked higher than
94% of the 551 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.22 vs. PETS: 23.95 )
PETS' s 10-Year ROE (%) Range
Min: -236.77   Max: 90.8
Current: 23.95

-236.77
90.8
ROA (%) 21.14
PETS's ROA (%) is ranked higher than
100% of the 563 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.09 vs. PETS: 21.14 )
PETS' s 10-Year ROA (%) Range
Min: -52.2   Max: 47.63
Current: 21.14

-52.2
47.63
ROC (Joel Greenblatt) (%) 111.19
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 562 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.27 vs. PETS: 111.19 )
PETS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -165.66   Max: 194.27
Current: 111.19

-165.66
194.27
Revenue Growth (3Y)(%) 4.40
PETS's Revenue Growth (3Y)(%) is ranked higher than
74% of the 494 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.70 vs. PETS: 4.40 )
PETS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 2.7   Max: 57.8
Current: 4.4

2.7
57.8
EBITDA Growth (3Y)(%) -1.60
PETS's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 462 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. PETS: -1.60 )
PETS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.7   Max: 109.3
Current: -1.6

-8.7
109.3
EPS Growth (3Y)(%) -0.70
PETS's EPS Growth (3Y)(%) is ranked higher than
70% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.20 vs. PETS: -0.70 )
PETS' s 10-Year EPS Growth (3Y)(%) Range
Min: -9   Max: 104.1
Current: -0.7

-9
104.1
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PETS Guru Trades in Q4 2013

Chuck Royce 141,000 sh (+151.79%)
John Hussman 20,000 sh (+33.33%)
Jim Simons 1,893,015 sh (+16.07%)
John Buckingham 121,889 sh (+2.27%)
Paul Tudor Jones Sold Out
» More
Q1 2014

PETS Guru Trades in Q1 2014

John Burbank 13,364 sh (New)
Paul Tudor Jones 33,500 sh (New)
Chuck Royce 351,500 sh (+149.29%)
John Hussman 26,000 sh (+30%)
John Buckingham 130,106 sh (+6.74%)
Jim Simons 1,817,208 sh (-4%)
» More
Q2 2014

PETS Guru Trades in Q2 2014

John Buckingham 132,974 sh (+2.2%)
Chuck Royce 351,500 sh (unchged)
Paul Tudor Jones Sold Out
John Hussman Sold Out
John Burbank Sold Out
Jim Simons 1,695,407 sh (-6.7%)
» More
Q3 2014

PETS Guru Trades in Q3 2014

John Buckingham 136,162 sh (+2.4%)
Chuck Royce 351,500 sh (unchged)
Jim Simons 1,589,215 sh (-6.26%)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Sold Out 0.03%$12.63 - $13.8 $ 146%0
John Burbank 2014-06-30 Sold Out $12.63 - $13.8 $ 146%0
John Hussman 2014-03-31 Add 30%0.01%$12.62 - $16.65 $ 140%26000
John Burbank 2014-03-31 New Buy$12.62 - $16.65 $ 140%13364
John Hussman 2013-12-31 Add 33.33%0.01%$14.58 - $16.86 $ 14-10%20000
Joel Greenblatt 2013-09-30 Sold Out 0.02%$12.82 - $17.17 $ 14-10%0
Joel Greenblatt 2013-06-30 Reduce -78.51%0.08%$12.37 - $13.73 $ 147%32909
John Hussman 2013-06-30 New Buy0.01%$12.37 - $13.73 $ 147%15000
Joel Greenblatt 2013-03-31 Add 39.37%0.03%$11.09 - $14.37 $ 1410%153161
Joel Greenblatt 2012-06-30 Add 162.75%0.06%$11.15 - $13.46 $ 1415%102679
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.50
PETS's P/E(ttm) is ranked higher than
85% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.50 vs. PETS: 16.50 )
PETS' s 10-Year P/E(ttm) Range
Min: 11.25   Max: 50.06
Current: 16.5

11.25
50.06
P/B 3.90
PETS's P/B is ranked higher than
61% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.32 vs. PETS: 3.90 )
PETS' s 10-Year P/B Range
Min: 2.33   Max: 20.8
Current: 3.9

2.33
20.8
P/S 1.20
PETS's P/S is ranked higher than
58% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. PETS: 1.20 )
PETS' s 10-Year P/S Range
Min: 0.84   Max: 3.51
Current: 1.2

0.84
3.51
PFCF 22.50
PETS's PFCF is ranked higher than
82% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.57 vs. PETS: 22.50 )
PETS' s 10-Year PFCF Range
Min: 7.86   Max: 1221.5
Current: 22.5

7.86
1221.5
EV-to-EBIT 8.81
PETS's EV-to-EBIT is ranked higher than
93% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.07 vs. PETS: 8.81 )
PETS' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 36.1
Current: 8.81

4.7
36.1
Shiller P/E 14.50
PETS's Shiller P/E is ranked higher than
94% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 31.75 vs. PETS: 14.50 )
PETS' s 10-Year Shiller P/E Range
Min: 9.84   Max: 124.94
Current: 14.5

9.84
124.94
Current Ratio 10.18
PETS's Current Ratio is ranked higher than
99% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.13 vs. PETS: 10.18 )
PETS' s 10-Year Current Ratio Range
Min: 0.29   Max: 17.46
Current: 10.18

0.29
17.46
Quick Ratio 7.47
PETS's Quick Ratio is ranked higher than
99% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.63 vs. PETS: 7.47 )
PETS' s 10-Year Quick Ratio Range
Min: 0.11   Max: 14.61
Current: 7.47

0.11
14.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.80
PETS's Dividend Yield is ranked higher than
91% of the 473 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.80 vs. PETS: 4.80 )
PETS' s 10-Year Dividend Yield Range
Min: 0.51   Max: 5.85
Current: 4.8

0.51
5.85
Dividend Payout 0.81
PETS's Dividend Payout is ranked higher than
61% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.61 vs. PETS: 0.81 )
PETS' s 10-Year Dividend Payout Range
Min: 0.31   Max: 1.21
Current: 0.81

0.31
1.21
Dividend growth (3y) 11.60
PETS's Dividend growth (3y) is ranked higher than
87% of the 389 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. PETS: 11.60 )
PETS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 11.6

0
26
Yield on cost (5-Year) 11.89
PETS's Yield on cost (5-Year) is ranked higher than
97% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.02 vs. PETS: 11.89 )
PETS' s 10-Year Yield on cost (5-Year) Range
Min: 1.26   Max: 14.5
Current: 11.89

1.26
14.5
Share Buyback Rate 4.00
PETS's Share Buyback Rate is ranked higher than
93% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. PETS: 4.00 )
PETS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -48.2
Current: 4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.70
PETS's Price/Net Cash is ranked higher than
99% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. PETS: 6.70 )
PETS' s 10-Year Price/Net Cash Range
Min: 3.77   Max: 34.59
Current: 6.7

3.77
34.59
Price/Net Current Asset Value 5.20
PETS's Price/Net Current Asset Value is ranked higher than
98% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. PETS: 5.20 )
PETS' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 236
Current: 5.2

3.12
236
Price/Tangible Book 4.00
PETS's Price/Tangible Book is ranked higher than
69% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.16 vs. PETS: 4.00 )
PETS' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 36.5
Current: 4

1.56
36.5
Price/DCF (Projected) 1.20
PETS's Price/DCF (Projected) is ranked higher than
90% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.57 vs. PETS: 1.20 )
PETS' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 6.04
Current: 1.2

0.54
6.04
Price/Median PS Value 0.80
PETS's Price/Median PS Value is ranked higher than
93% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. PETS: 0.80 )
PETS' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 1.95
Current: 0.8

0.14
1.95
Price/Graham Number 1.70
PETS's Price/Graham Number is ranked higher than
79% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.46 vs. PETS: 1.70 )
PETS' s 10-Year Price/Graham Number Range
Min: 1.06   Max: 5.73
Current: 1.7

1.06
5.73
Earnings Yield (Greenblatt) 11.40
PETS's Earnings Yield (Greenblatt) is ranked higher than
93% of the 557 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.10 vs. PETS: 11.40 )
PETS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.8   Max: 21.2
Current: 11.4

2.8
21.2
Forward Rate of Return (Yacktman) 2.20
PETS's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 437 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.45 vs. PETS: 2.20 )
PETS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 65.7
Current: 2.2

0.7
65.7

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 227 223
EPS($) 0.86 0.82
EPS without NRI($) 0.86 0.82

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, GNC, APNHY, JCOUF, PMC » details
Traded in other countries:PQM.Germany,
PetMed Express, Inc. was incorporated in the state of Florida in January 1996. The company is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. The Company offers consumers an alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. Its current product line contains approximately 3000 SKUS. These products include a majority of the well-known brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl. These pet supplies include: food, beds, crates, stairs, strollers, and other popular pet supplies. Its website allows customers to easily browse and purchase all of its products online. Its operations are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy.
» More Articles for PETS

Headlines

Articles On GuruFocus.com
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PETS Mar 02 2013 
comment on PETS Mar 02 2013 
PetMed Express - Debt-Free with Attractive Dividend Yield Nov 26 2012 
comment on PETS Nov 13 2012 

More From Other Websites
PETMED EXPRESS INC Financials Nov 04 2014
10-Q for PetMed Express, Inc. Oct 30 2014
PetMed Disappoints in Q2 on Low New and Reorder Sales Oct 30 2014
PETMED EXPRESS INC Files SEC form 10-Q, Quarterly Report Oct 28 2014
Cannabis Therapy Gears Up Canna-Pet Business Oct 23 2014
PetMed Posts Dismal Q2, Lags on Earnings and Revenues Oct 22 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 21 2014
PetMed’s results hurt by shortened flea and tick season — seriously? Oct 20 2014
[$$] PetMed Posts Lower Earnings Oct 20 2014
PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS SECOND QUARTER FINANCIAL RESULTS AND ITS $0.17 PER... Oct 20 2014
PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS SECOND QUARTER FINANCIAL RESULTS ON OCTOBER 20,... Oct 20 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events Oct 20 2014
PetMed misses Street 2Q forecasts Oct 20 2014
PetMed misses Street 2Q forecasts Oct 20 2014
PetMed Express D/B/A 1-800-PetMeds Announces Its Second Quarter Financial Results and Its $0.17 Per... Oct 20 2014
Q2 2014 Petmed Express Inc Earnings Release - 08:00 am ET Oct 20 2014
Why PetMed Express (PETS) Might Surprise This Earnings Season Oct 16 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events Oct 14 2014
PetMed Express D/B/A 1-800-PetMeds to Announce Its Second Quarter Financial Results on October 20,... Oct 13 2014
Stock Futures Point Lower; Recalls Trip Up Hertz Global Aug 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK